Sartorius Stedim Biotech SA
DIM
Company Profile
Business description
Sartorius Stedim Biotech is a leading provider of bioprocessing solutions. Its sells equipment and consumables for fermentation, filtration, fluid management, purification, and cell culture media for manufacturing biologic drugs and has a focus on single-use technology. It is a subsidiary of Sartorius AG, which has 71.5% ownership and 83% voting control. The business is geographically diverse, with 35% of sales from the Americas, 42% from Europe, the Middle East, and Africa, 15% from Asia excluding China, and 8% from China.
Contact
Otto-Brenner-Strasse 20
Goettingen37079
DEUT: +49 5513080
Sector
Healthcare
Stock type
Defensive
Industry
Medical Instruments & Supplies
Fiscal Year End
31 December 2026
Employees
10,265
Stocks News & Analysis
stocks
Chart of the Week: Has gold reached bear market territory?
Investors are facing a shifting landscape.
stocks
Fair value upgrade for this ASX income player
Headwinds in listed energy stocks likely to have passed
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,885.60 | 59.90 | 0.68% |
| CAC 40 | 7,929.02 | 112.08 | 1.43% |
| DAX 40 | 23,069.69 | 389.65 | 1.72% |
| Dow JONES (US) | 46,341.51 | 1,125.37 | 2.49% |
| FTSE 100 | 10,345.60 | 169.15 | 1.66% |
| HKSE | 25,260.76 | 472.62 | 1.91% |
| NASDAQ | 21,590.63 | 795.99 | 3.83% |
| Nikkei 225 | 53,739.68 | 2,675.96 | 5.24% |
| NZX 50 Index | 12,825.87 | 86.24 | -0.67% |
| S&P 500 | 6,528.52 | 184.80 | 2.91% |
| S&P/ASX 200 | 8,671.80 | 53.10 | 0.62% |
| SSE Composite Index | 3,948.55 | 56.69 | 1.46% |